Tag: Imugene
Imugene: Progresses VAXINIA trial in December quarter
Imugene Progresses VAXINIA trial in December quarterImugene (IMU) has taken another step forward in its efforts to treat...
Imugene: Receives VAXINIA ethics approval in Australia
Imugene Receives VAXINIA ethics approval in AustraliaImugene (IMU) receives Human Research Ethics Committee (HREC) approval to commence a...
Imugene: Presents fresh onCARlytics data at SITC annual meeting
Imugene Presents fresh onCARlytics data at SITC annual meetingImugene (IMU) presents new data for its onCARlytics oncolytic virus...
Imugene: Generates income of $5.34m in H1 FY22
Imugene Generates income of $5.34m in H1 FY22Imugene (IMU) records an income of more than $5.34 million for...
Imugene: Receives $4.8M tax rebate on cancer research
Clinical-stage immuno-oncology company Imugene (IMU) has received a hefty tax rebate for its research and development (R&D) spending
...
Imugene: Receives FDA approval for PD1-Vaxx trial
Imugene (IMU) has received approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial...
Imugene: Receives key U.S. patent for cancer therapies
Imugene (IMU) shares are trading green today on news the healthcare stock was granted a core U.S. patent
...
Imugene: Signs $5.7M option underwriting agreement
Imugene (IMU) has secured a $5.7 million option underwriting agreement with Bell Potter
The agreement between the company...
Imugene: Receives clinical guidance from U.S. FDA for VAXinia
Imugene has received guidance from the U.S. Food and Drug Administration (FDA) for the development of VAXinia
The...
Imugene: Secures approval for PD1-Vaxx trial
Imugene: Secures approval for PD1-Vaxx trialImugene has received a second Human Research Ethics Committee approval to begin a...
Imugene: Receives ethics approval for PD1-Vaxx trial
Imugene: Receives ethics approval for PD1-Vaxx trialBiotech company Imugene has received Human Research Ethics Committee (HREC) approval to...